title: Clinical outcomes of dexamethasone-eluting stent implantation in ST-elevation acute myocardial infarction.
abstract: OBJECTIVE
  The aim of our study was to evaluate the safety and midterm clinical results of dexamethasone-eluting stent (DexES) implantation in ST-segment elevation acute myocardial infarction (STEMI).
  
  
  BACKGROUND
  Inflammation plays a pivotal role in both inestabilization of coronary atherosclerotic plaques and development of restenosis after stent placement. Antiinflammatory agents may attenuate those mechanisms and improve clinical outcomes. There is little information about clinical results of DexES and no data are available about their utilization during percutaneous coronary intervention (PCI) in STEMI.
  
  
  METHODS
  Consecutive patients with STEMI that underwent primary or rescue PCI in our institution were treated with DexES. Clinical follow-up with routine realization of noninvasive test for detection of myocardial ischemia and coronariography if necessary, were performed. The objective of the study was to evaluate the rate of MACE (death, reinfarction, or target lesion revascularization) during midterm follow-up.
  
  
  RESULTS
  The procedure was successful in 96.7% of cases. There were no in-hospital deaths or reinfarctions. One acute stent thrombosis occurred and no subacute thrombosis were observed. During a mean follow-up period of 384 days, cardiac-related death was 1.1%, there were no reinfarctions or late stent thrombosis and target lesion revascularization rate was 4.2%.
  
  
  CONCLUSIONS
  We conclude that utilization of DexES for PCI in STEMI is safe and provides good midterm clinical outcomes.
authors: Cardiology Department, Hospital Virgen de la Salud, Toledo, Spain.
authors: Santiago
authors: S
authors: Jimenez-Valero
authors: Belen
authors: B
authors: Santos
authors: Fernando
authors: F
authors: Pajin
authors: Tomas
authors: T
authors: Canton
authors: Esther
authors: E
authors: Lazaro
authors: Jose
authors: J
authors: Moreu
authors: Gonzalo
authors: G
authors: Hernandez
authors: Luis Rodriguez
authors: LR
authors: Padial
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000295:instrumentation*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002317:Cardiovascular Agents / Q000008:administration & dosage*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003907:Dexamethasone / Q000008:administration & dosage* / Q000009:adverse effects; D054855:Drug-Eluting Stents; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D055502:Secondary Prevention; D013318:Stroke Volume; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D013997:Time Factors; D016896:Treatment Outcome; D016277:Ventricular Function, Left; D017725:Ventricular Pressure
chemical_list: D000893:Anti-Inflammatory Agents; D002317:Cardiovascular Agents; D003907:Dexamethasone